Medical science today offers advanced cures and long-term control for cancer, yet the financial burden of treatment continues to deny access to thousands of patients across India. Despite government initiatives and medical breakthroughs, the high cost of therapies pushes families into despair and forces difficult choices about continuing care.
Alarming Cancer Statistics and Projections
India reported 15.33 lakh new cancer cases in 2024, according to data from the Indian Council of Medical Research–National Cancer Registry Programme (ICMR-NCRP). Even more concerning are projections warning of a 67% rise in cancer cases by 2045, driven primarily by lifestyle-linked risks and an ageing population. This growing health crisis demands urgent attention to both prevention and treatment accessibility.
The Heavy Financial Toll on Patients
A comprehensive study conducted by the Post-Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, across seven major cancer centers reveals the staggering financial burden faced by patients. The research, conducted at premier institutions including AIIMS New Delhi, Tata Memorial Centre Mumbai, Kidwai Memorial Institute of Oncology Bengaluru, Regional Cancer Centre Thiruvananthapuram, Chittaranjan National Cancer Institute Kolkata, Dr B Borooah Cancer Institute Guwahati, and PGIMER itself, found that patients spend an average of ₹3 lakh annually out of pocket.
Diagnostics and medicines account for nearly two-thirds of this total expenditure, creating an insurmountable barrier for many families. For countless households, this financial burden forces delays or complete abandonment of therapy, despite the availability of potentially life-saving treatments.
Government Initiatives and Their Limitations
The government has taken some steps to address this crisis, including removing customs duty on select high-cost medicines in the 2026 Union Budget. This measure exempted 17 cancer drugs, including advanced targeted therapies like ribociclib and abemaciclib, from basic customs duty with the aim of lowering costs for patients dependent on imported treatments.
However, even with these duty exemptions, advanced targeted therapies continue to cost several lakhs per year, placing them out of reach for many Indian families. The gap between medical advancement and affordability remains substantial.
State-Level Success Stories
Some states have implemented innovative models to improve cancer treatment affordability. Kerala's Karunya Sparsham zero-profit drug outlets, launched in 2024 and expanded to 72 counters statewide by 2025, provide oncology medicines at discounts of more than 90 percent. This state-led initiative demonstrates how targeted approaches can significantly improve access to essential medications.
Dr K C Jyothish, Consultant Radiation Oncologist at VS Hospitals in Chennai, emphasizes the critical nature of this affordability gap. "The cure is there. But so is the cost. Unless we bridge this gap, medical advances will remain invisible to the patient who cannot afford them," he stated, highlighting the urgent need for systemic solutions.
Insurance Coverage and Its Challenges
Insurance schemes such as Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (PM-JAY) have expanded coverage for cancer patients, offering cashless treatment in empaneled hospitals across the country. This represents significant progress in making cancer care more accessible to economically disadvantaged populations.
Despite these advances, insurance penetration remains uneven across different regions and socioeconomic groups. Many families still face catastrophic out-of-pocket expenses that can devastate household finances and force impossible choices between treatment and basic necessities.
The Crucial Role of Prevention
While treatment affordability remains a critical challenge, public health initiatives focused on prevention and early detection continue to play a vital role in combating cancer. HPV vaccination campaigns, comprehensive tobacco control measures, and widespread screening programmes remain crucial components of India's cancer control strategy.
These preventive measures not only reduce the incidence of cancer but also enable earlier detection when treatment is typically more effective and less expensive. Investing in prevention represents both a health imperative and a financial strategy to reduce the long-term burden of cancer care.
The Path Forward: Policy Recommendations
Oncology experts argue that unless policies are strengthened across multiple fronts, the promise of a cancer cure will remain an unaffordable privilege rather than a universal right. Key recommendations include:
- Lowering drug costs through price controls, bulk procurement, and incentives for generic production
- Expanding insurance coverage to reach more vulnerable populations and cover a broader range of treatments
- Boosting domestic production of cancer medications to reduce dependence on expensive imports
- Strengthening public health infrastructure for early detection and prevention programmes
As India faces a growing cancer burden, the intersection of medical advancement and financial accessibility will determine whether cutting-edge treatments reach those who need them most. The challenge extends beyond medical science to encompass economic policy, healthcare financing, and social equity.
